Role of aggressive surgical cytoreduction in advanced ovarian cancer

Suk Joon Chang, Robert E. Bristow, Dennis S. Chi, William Arthur Cliby

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Ovarian cancer is the eighth most frequent cancer in women and is the most lethal gynecologic malignancy worldwide. The majority of ovarian cancer patients are newly diagnosed presenting with advanced-stage disease. Primary cytoreductive surgery and adjuvant taxane- and platinum-based combination chemotherapy are the standard treatment for advanced ovarian cancer. A number of studies have consistently shown that successful cytoreductive surgery and the resultant minimal residual disease are significantly associated with survival in patients with this disease. Much has been written and even more debated regarding the competing perspectives of biology of ovarian cancer versus the value of aggressive surgical resection. This review will focus on the current evidences and outcomes supporting the positive impact of aggressive surgical effort on survival in the primary management of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)336-342
Number of pages7
JournalJournal of Gynecologic Oncology
Volume26
Issue number4
DOIs
StatePublished - Oct 1 2015

Fingerprint

Ovarian Neoplasms
Survival
Residual Neoplasm
Combination Drug Therapy
Platinum
Neoplasms
Therapeutics

Keywords

  • Cytoreduction surgical procedures
  • Neoplasm
  • Ovarian neoplasms
  • Residual

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Role of aggressive surgical cytoreduction in advanced ovarian cancer. / Chang, Suk Joon; Bristow, Robert E.; Chi, Dennis S.; Cliby, William Arthur.

In: Journal of Gynecologic Oncology, Vol. 26, No. 4, 01.10.2015, p. 336-342.

Research output: Contribution to journalArticle

Chang, Suk Joon ; Bristow, Robert E. ; Chi, Dennis S. ; Cliby, William Arthur. / Role of aggressive surgical cytoreduction in advanced ovarian cancer. In: Journal of Gynecologic Oncology. 2015 ; Vol. 26, No. 4. pp. 336-342.
@article{d6405fd58b5b49eab5fcbd0cd90eccc7,
title = "Role of aggressive surgical cytoreduction in advanced ovarian cancer",
abstract = "Ovarian cancer is the eighth most frequent cancer in women and is the most lethal gynecologic malignancy worldwide. The majority of ovarian cancer patients are newly diagnosed presenting with advanced-stage disease. Primary cytoreductive surgery and adjuvant taxane- and platinum-based combination chemotherapy are the standard treatment for advanced ovarian cancer. A number of studies have consistently shown that successful cytoreductive surgery and the resultant minimal residual disease are significantly associated with survival in patients with this disease. Much has been written and even more debated regarding the competing perspectives of biology of ovarian cancer versus the value of aggressive surgical resection. This review will focus on the current evidences and outcomes supporting the positive impact of aggressive surgical effort on survival in the primary management of ovarian cancer.",
keywords = "Cytoreduction surgical procedures, Neoplasm, Ovarian neoplasms, Residual",
author = "Chang, {Suk Joon} and Bristow, {Robert E.} and Chi, {Dennis S.} and Cliby, {William Arthur}",
year = "2015",
month = "10",
day = "1",
doi = "10.3802/jgo.2015.26.4.336",
language = "English (US)",
volume = "26",
pages = "336--342",
journal = "Journal of Gynecologic Oncology",
issn = "2005-0380",
publisher = "Korean Society of Gynecologic Oncology and Colposcopy",
number = "4",

}

TY - JOUR

T1 - Role of aggressive surgical cytoreduction in advanced ovarian cancer

AU - Chang, Suk Joon

AU - Bristow, Robert E.

AU - Chi, Dennis S.

AU - Cliby, William Arthur

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Ovarian cancer is the eighth most frequent cancer in women and is the most lethal gynecologic malignancy worldwide. The majority of ovarian cancer patients are newly diagnosed presenting with advanced-stage disease. Primary cytoreductive surgery and adjuvant taxane- and platinum-based combination chemotherapy are the standard treatment for advanced ovarian cancer. A number of studies have consistently shown that successful cytoreductive surgery and the resultant minimal residual disease are significantly associated with survival in patients with this disease. Much has been written and even more debated regarding the competing perspectives of biology of ovarian cancer versus the value of aggressive surgical resection. This review will focus on the current evidences and outcomes supporting the positive impact of aggressive surgical effort on survival in the primary management of ovarian cancer.

AB - Ovarian cancer is the eighth most frequent cancer in women and is the most lethal gynecologic malignancy worldwide. The majority of ovarian cancer patients are newly diagnosed presenting with advanced-stage disease. Primary cytoreductive surgery and adjuvant taxane- and platinum-based combination chemotherapy are the standard treatment for advanced ovarian cancer. A number of studies have consistently shown that successful cytoreductive surgery and the resultant minimal residual disease are significantly associated with survival in patients with this disease. Much has been written and even more debated regarding the competing perspectives of biology of ovarian cancer versus the value of aggressive surgical resection. This review will focus on the current evidences and outcomes supporting the positive impact of aggressive surgical effort on survival in the primary management of ovarian cancer.

KW - Cytoreduction surgical procedures

KW - Neoplasm

KW - Ovarian neoplasms

KW - Residual

UR - http://www.scopus.com/inward/record.url?scp=84944563924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944563924&partnerID=8YFLogxK

U2 - 10.3802/jgo.2015.26.4.336

DO - 10.3802/jgo.2015.26.4.336

M3 - Article

C2 - 26197773

AN - SCOPUS:84944563924

VL - 26

SP - 336

EP - 342

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

SN - 2005-0380

IS - 4

ER -